Have a personal or library account? Click to login
Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma Cover

Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma

Forum of Clinical Oncology
Volume 5 (2014): Issue 1 (July 2014)
By: R Gaafar,  H Khaled,  Y.A. Sallam,  H Shafik,  F.A. Aboulkassem and  M Emara  
Open Access
|Aug 2014

References

  1. [1] Gaafar R, Aly Ely Eldin N; Epidemic of mesothelioma in Egypt, Lung Cancer, 2005, 49S1, S17-S20.10.1016/j.lungcan.2005.03.025
    Search in Google Scholar
  2. [2] Abou El-Kasem F, Gaafar R, Abdel-Rahman A, Abdel-Baki H, Hassan N. Malignant pleural mesothelioma: analysis of 100 consecutive patients. Lung Cancer 2004, 45(3):s67.
    Search in Google Scholar
  3. [3] Porret E, Madelaine J, Galateau-Salle F, et al. Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007-an update. Rev Mal Respir 2007; 24:6S157-64. [PubMed]10.1016/S0761-8425(07)78149-4
    Search in Google Scholar
  4. [4] Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-9.10.1183/09031936.00039510
    Search in Google Scholar
  5. [5] Hillerdal G, Sorensen JB, Sundstrom S, et al. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008; 3:1325-[6] van Meerbeeck JP, Baas P, Debruyne C, et al: EORTC Lung Cancer Group. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 2002, 38, 779-783.
    Search in Google Scholar
  6. [7] Habib EE, Fahmy ES. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens. Clin Transl Oncol. 2013 [Epub ahead of print] [PubMed]10.1007/s12094-013-1015-3
    Search in Google Scholar
  7. [8] van Meerbeeck J, Debruyne C, van Zandwijk N, et al: Paclitaxel for malignant pleural mesothelioma: A phase II studies of the EORTC Lung Cancer Cooperative Group. Br J Cancer, 1996, 74, 961-963.10.1038/bjc.1996.465
    Search in Google Scholar
  8. [9] Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95.10.1183/09031936.00063109
    Search in Google Scholar
  9. [10] Sahmoud T, Postmus PE, van Pottelsberghe C, et al: G. Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer,1997, 33, 2211-2115.10.1016/S0959-8049(97)00183-4
    Search in Google Scholar
  10. [11] Ellis P, Davies AM, Evans WK, etal: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systemic review and practice guide lines. J Thoracic Oncol, 2006, 1(6), 591-601.10.1016/S1556-0864(15)30366-X
    Search in Google Scholar
  11. [12] Shin DM, Scagliotti GV, Kindler HL, et al: A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: Clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc Am Soc Clin Oncol, 2002, 21, 294 (abstr 1175).
    Search in Google Scholar
  12. [13] Vogelzang N, Rusthoven J., Symanowski J., etal phase III Study of Pemetrexed in Combination With CisplatinVersus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, J Clin Oncol 2003, 21, 2636-2644.10.1200/JCO.2003.11.136
    Search in Google Scholar
  13. [14] Baas P, Ardizzoni A, Grossi F, et al: EORTC Lung Cancer Group: The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: An EORTC phase II study (08992). Eur J Cancer 2003, 39, 353-357.10.1016/S0959-8049(02)00668-8
    Search in Google Scholar
  14. [15] Fizazi K, Doubre H, Le Chevalier T, et al: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study. J Clin Oncol 2003, 21, 349- 354.10.1200/JCO.2003.05.12312525529
    Search in Google Scholar
  15. [16] van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase IIIstudy of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23: 6881-9.10.1200/JCO.20005.14.58916192580
    Search in Google Scholar
  16. [17] Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443.10.1200/JCO.2005.04.319016549838
    Search in Google Scholar
  17. [18] Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370.10.1093/annonc/mdm50118156144
    Search in Google Scholar
  18. [19] Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756.10.1097/JTO.0b013e31817c73d618594322
    Search in Google Scholar
  19. [20] Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol 2011; 6:1950-4.10.1097/JTO.0b013e3182333df522005473
    Search in Google Scholar
  20. [21] Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30:2509-15.10.1200/JCO.2011.41.5869339778522665541
    Search in Google Scholar
  21. [22] Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 201; 37:543-58. [PubMed]10.1016/j.ctrv.2011.01.00121288646
    Search in Google Scholar
DOI: https://doi.org/10.2478/fco-2014-0005 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 29 - 36
Published on: Aug 14, 2014
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Mesothelioma,
Egypt,
Chemotherapy
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2014 R Gaafar, H Khaled, Y.A. Sallam, H Shafik, F.A. Aboulkassem, M Emara, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 5 (2014): Issue 1 (July 2014)